Key facts
- It has raised $16.1M across 2 recorded rounds; the latest was Early Stage VC ($7.5M) in Nov 2020.
- Notable investors include National Institutes of Health, Keiretsu Forum, SideCar Angels, Alzheimers Drug Discovery Foundation, Boston Harbor Angels — 28 tracked in total.
- Astrocyte Pharmaceuticals has filed 2 Form Ds with the SEC since 2020, most recently Oct 2022 ($2.8M sold to 48 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Astrocyte Pharmaceuticals
Funding rounds
2 roundsAbout Astrocyte Pharmaceuticals
Developer of neuroprotective therapies intended to advance treatment for brain injuries and neurodegenerative disorders. The company platform offers research-driven programs focused on astrocyte biology, clinical trial development, and therapeutic approaches for conditions such as stroke, concussion, and traumatic brain injury, enabling healthcare providers and researchers to access scientifically validated methods that improve patient outcomes, reduce long-term neurological damage, and expand treatment options for complex brain disorders.
- Sector
- Healthcare
- HQ
- Groton, CT, United States
- Founded
- 2014
- Employees
- 9
- Website
- astrocytepharma.com/
- Ownership
- Privately Held (backing)
Astrocyte Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Astrocyte Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Astrocyte Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.